Carrier-Free Nanomedicine for Cancer Immunotherapy

Area of Science:

• Nanotechnology and Nanomedicine
• Cancer Immunotherapy
• Drug Delivery Systems

Background:

• Carrier-based nano-drug delivery systems (DDSs) show promise but face limitations like low drug loading, toxicity, and unclear metabolism.
• These limitations hinder clinical translation of traditional DDSs.
• Carrier-free nanomedicines emerge as a superior alternative, enhancing drug delivery efficacy and safety without non-therapeutic excipients.

Purpose of the Study:

• To provide a comprehensive overview of recent advancements in carrier-free nanomedicines for cancer immunotherapy.
• To discuss synthetic strategies, applications, advantages, challenges, and future prospects of these novel systems.

Main Methods:

• Review of recent scientific literature on carrier-free nanomedicines.
• Introduction to synthesis methods including nanocrystals, prodrugs, amphiphilic drug-drug conjugates (ADDCs), polymer-drug conjugates, and peptide-drug conjugates (PepDCs).
• Discussion of applications in cancer vaccines, cytokine therapy, T-cell checkpoint inhibition, and tumor microenvironment (TME) modulation.

Main Results:

• Carrier-free nanomedicines demonstrate significant progress in cancer immunotherapy.
• Various synthetic strategies enable tailored nanomedicine design.
• Applications span diverse areas of cancer immunotherapy, showing enhanced efficacy and safety profiles.

Conclusions:

• Carrier-free nanomedicines represent a promising paradigm shift in cancer immunotherapy, overcoming limitations of carrier-based systems.
• Continued research into synthesis, applications, and addressing challenges will unlock their full clinical potential.
• These systems hold great potential for clinical practice and reference in related scientific fields.